

32. Screening for Rubella— Including Immunization of Adolescents and Adults

RECOMMENDATION

Routine screening for rubella susceptibility by history of vaccination or by serology is recommended for all women of childbearing age at their first clinical encounter. Susceptible nonpregnant women should be offered rubella vaccination; susceptible pregnant women should be vaccinated immediately after delivery. An equally acceptable alternative for nonpregnant women of childbearing age is to offer vaccination against rubella without screening (see *Clinical Intervention*). There is insufficient evidence to recommend for or against screening or routine vaccination of young men in settings where large numbers of susceptible young adults of both sexes congregate, such as military bases and colleges. Routine screening or vaccination of other young men, of older men, and of postmenopausal women is not recommended.

Burden of Suffering

Rubella is generally a mild illness; when contracted by pregnant women, however, especially those in the first 16 weeks of pregnancy, it frequently causes serious complications including miscarriage, abortion, stillbirth, and congenital rubella syndrome (CRS).^{1,2} The 1964 rubella pandemic in the U.S. caused over 12 million infections, 11,000 fetal losses, and 20,000 cases of CRS in infants.³ The most common manifestations of CRS are hearing loss, developmental delay, growth retardation, and cardiac and ocular defects.^{1,2} The lifetime costs of treating a patient with CRS were estimated in 1985 to exceed \$220,000.³

Since 1969, when rubella vaccine became available in the U.S. and universal childhood immunization was initiated, no major periodic rubella epidemics have occurred. The incidence of reported cases has declined dramatically, to an estimated incidence rate of 0.1/100,000 population (192 cases) and an indigenous CRS incidence rate of 0/100,000 live births (no cases reported) in 1993.⁴ Outbreaks of rubella infection have continued to occur, however; in 1991, for example, 1,401 rubella infections were

reported (0.6/100,000), one third of which occurred among adolescents and young adults (ages 15–29 years), resulting in 31 cases of CRS (0.8/100,000).^{4,5} Most recent outbreaks have occurred in settings where many unvaccinated children and young adults are gathered (e.g., religious communities that refuse vaccination, colleges, prisons, and work places), and among persons in specific racial/ethnic groups (e.g., Asians/Pacific Islanders and Hispanics) who are often unvaccinated.^{4,6,7} The highest risk for CRS occurs in Amish women, for whom the rate in one Pennsylvania county was 14/1,000 live births in 1991, compared to 0.006/1,000 for the general U.S. population.⁴

Accuracy of Screening Tests

One way to prevent rubella infection in adults is to screen for susceptibility, by serologic tests for antibodies or by vaccination history, and to administer vaccine to susceptible persons. Vaccine trials and cohort studies have shown that most patients with hemagglutination-inhibition (HI) antibody are protected from clinical disease.^{8–10} HI is a labor-intensive test, however, and it can be associated with both false-positive and false-negative results.^{1,8,11} Faster, more convenient laboratory methods (e.g., enzyme immunoassay and latex agglutination) have now replaced HI in most laboratories.^{1,12} Using HI as the comparison standard, these tests have sensitivities of 92–100% and specificities of 71–100%.^{11,13–15} The apparently low specificities of some newer methods are due to their ability to detect low levels of rubella antibody that are undetectable by HI methods and are therefore reported as “false positives.”^{1,16,17} There have been no controlled trials to determine if these low levels confer immunity against wild virus,¹ but other clinical and in vitro evidence suggests that they are protective.^{16,18–22} These newer tests, therefore, appear to be both more accurate and more convenient than HI when performed in laboratories with demonstrated proficiency.

A history of rubella vaccination can identify many who may be protected. Despite a variety of design flaws in some of the available studies (such as selection biases and small sample sizes), most demonstrate that persons with a positive history of having received rubella vaccine are significantly more likely to be seropositive (median 92%, range 82–97%) than those without such a history (median 74%, range 62–83%).^{18,23–30} A positive rubella vaccination history documented by vaccination card, school record, or medical record is more likely to be associated with seropositivity than is an undocumented history (although this difference was not statistically significant in some studies),^{18,25–27} and it is therefore preferred. A positive history of rubella infection is substantially less likely to correctly predict rubella immunity than is a positive history of vaccina-

tion,^{18,23–25} therefore, a history of infection is not adequate for determining susceptibility.

Effectiveness of Early Detection

Rubella vaccine, once administered, is efficacious. Efficacy studies in healthy vaccinees show that 90% have protection against clinical rubella illness,^{31–35} and seropositivity is long-lasting.^{36–39} After the initiation of universal child immunization in 1969, the incidence of both rubella and CRS dropped markedly (see above).^{1,4} Adverse reactions from the RA27/3 live attenuated rubella vaccine (the only rubella vaccine currently licensed in the U.S.) are generally mild in children.^{40,41} Joint symptoms after vaccination are common in adults but rarely persist; the incidence is higher in women than men and increases with increasing age at vaccination.^{1,9,42,43} Vaccination of persons who are already immune rarely induces the joint symptoms seen with primary immunization of susceptible adults.^{44,45}

Because an estimated 6–12% of the young adult population is seronegative,^{30,46} and because CRS continues to occur in the U.S. despite recommendations for universal childhood vaccination (see Chapter 65),⁴ it has been recommended by some authorities that clinicians also direct efforts toward vaccinating susceptible adolescents and young adults, particularly women of childbearing age.¹ Several factors may reduce the effectiveness of a strategy to prevent CRS by screening (with history of vaccination or serology) and vaccinating susceptibles. The screening test may falsely identify some susceptible persons as immune; of 21 infants with CRS in 1990, 71% of their mothers had had a positive serologic test and 43% gave a history of vaccination.⁴⁷ Persons correctly identified as susceptible may not be offered or accept the vaccine; vaccination rates after serologic screening in different populations have ranged from 37% to 88%.^{18,24,26,27,48–56} Seronegative women are more likely than are seronegative men to accept immunization,^{55,57} with the highest rates of follow-up vaccination (78–87%) occurring in susceptible postpartum women.^{52–54}

The effectiveness of a strategy of screening and follow-up vaccination to prevent CRS may be assessed by its effect on the incidence of CRS and of rubella infection and susceptibility in women of childbearing age. No controlled studies have evaluated the effectiveness of screening and vaccinating susceptible persons in reducing the incidence of CRS. CRS occurrence has decreased over time in some, but not all, countries that have employed selective vaccination of susceptible adolescent and adult females as their sole strategy to reduce CRS.^{58–60} Evidence that screening and follow-up vaccination can reduce the likelihood of rubella infection was provided by a severe rubella outbreak in Iceland, where identical rates of

protection from infection occurred in screened and immunized (98.5%) and in naturally immune (99%) schoolgirls.⁶¹ Evidence regarding rubella susceptibility is supplied by a cohort study from Scotland. Six to seven years after a screening program for schoolgirls took place, 98.7% of girls who had originally been naturally immune had circulating antibodies, compared to 95.1% of those who had been vaccinated as susceptibles and 42.8% of a small group of susceptibles who had refused vaccination.⁶² Case series from Iceland^{61,63} and cross-sectional studies from Great Britain^{52,64} also show a reduction in susceptibility among women of childbearing age using this strategy. There is thus fair evidence that screening and immunizing susceptible females of childbearing age reduces both rubella susceptibility and infection and, by inference, CRS.

An alternative strategy to prevent rubella infection in women of childbearing age is routine vaccination without screening. In addition to protecting those who have not been previously vaccinated, such a strategy would eliminate most susceptibility due to primary vaccine failure (failure to develop antibodies after initial vaccination). Primary vaccine failure occurs in 2–5% of RA27/3 vaccine recipients,^{65–70} and a second rubella vaccination results in seroconversion in most cases.^{9,18} Antibodies have been found in 99.2% of schoolchildren after two doses of rubella vaccine, compared to 94.6% after one dose.²⁸ In Sweden and Finland, vaccine programs in which all adolescent girls are routinely immunized (as well as all children at age 14–18 months) have been associated with substantially reduced occurrence of both seronegativity and of rubella infection in female compared to male adolescents and adults.^{71,72} These data provide fair evidence for routine vaccination of all nonpregnant women of childbearing age to reduce rubella susceptibility and infection and, therefore, CRS.

The rubella vaccine is contraindicated during pregnancy because of the theoretical possibility of teratogenicity, although there have been no reported cases of rubella vaccine-related birth defects in the United States after inadvertent vaccination of 321 susceptible pregnant women within 3 months of conception.¹ Similarly reassuring results have been reported from Great Britain and Germany.^{73,74} Based on reported data, the true risk for CRS in susceptible women vaccinated during pregnancy using the RA27/3 vaccine may be zero, and the probability is 95% that the true risk is less than 1.7%.⁷⁵ Because a measurable iatrogenic risk cannot be excluded, however, vaccination of susceptible women who are known to be pregnant should be postponed until the postpartum period.⁷⁵ The virus has been isolated in breast milk and in breast-fed infants after postpartum vaccination,⁷⁶ but no adverse consequences from such exposure have been reported.^{76,77} A greater disadvantage of postpartum immunization is that it often occurs too late to prevent CRS; 61% of reported cases have occurred with the first live birth.⁷⁸

In settings where large numbers of young adults are gathered (e.g., military bases and colleges), outbreaks of rubella are not uncommon, and males and females are infected at similar rates.^{79–82} Rubella screening or routine vaccination of young men in such settings might reduce the risk of spreading rubella to susceptible pregnant women. There is weak evidence from a single before-after study that universal rubella screening and follow-up vaccination of military recruits is effective in preventing rubella infection and eliminating epidemic rubella.⁸³ A small cohort study using the older Cendehill vaccine found that routine vaccination of young male military recruits reduced rubella susceptibility, clinical disease, and viral shedding.¹⁰ In a before-after study of 256 college athletes (62% male) screened serologically with follow-up vaccination of susceptibles, the proportion with documented immunity by serology increased from 93% to 96%, and 8 of the remaining 9 seronegative students were vaccinated but did not receive follow-up testing.⁸⁴ There is, however, no direct evidence that either screening or routine vaccination of males in these settings reduces CRS. For young men not living in such settings, no evidence was found to support either screening or routine vaccination in reducing susceptibility, infection, or CRS.

There are few data concerning rubella screening or vaccination in older men or in women past childbearing age. Because men ages 40 years and older and postmenopausal women account for only a small proportion (<10%) of recent rubella cases,^{5,85} have a high rate of natural immunity (85–95%),^{59,86} have a greater likelihood of postvaccine joint reactions,⁹ and are at little direct risk if they do become infected, routine screening or vaccination of this population does not seem to be justified despite the fact that these persons might, on rare occasions, transmit rubella to susceptible women of childbearing age.

Recommendations of Other Groups

The American Academy of Pediatrics (AAP),⁸⁷ American College of Obstetricians and Gynecologists (ACOG),⁸⁸ American College of Physicians,⁸⁹ and Advisory Committee for Immunization Practices (ACIP)¹ recommend vaccinating all adolescents and adults (particularly women and persons in colleges, health care settings, and military institutions) who have no contraindications and who lack documented evidence of either rubella immunization on or after the first birthday or of serologic evidence of immunity. Routine serologic testing of men and nonpregnant women is not recommended by these organizations. The American Medical Association⁹⁰ and Bright Futures⁹¹ recommend rubella vaccination (as measles-mumps-rubella [MMR]) for all adolescents who have not had two previous MMR vaccinations. The American Academy of Family Physicians recom-

mends rubella antibody testing in all women of childbearing age who lack evidence of immunity.⁹² AAP,⁸⁷ ACOG,⁸⁹ and ACIP¹ recommend routine prenatal or antepartum serologic screening of all pregnant women not known to be immune, and postpartum vaccination of those found to be susceptible. The Canadian Task Force on the Periodic Health Examination recommends serologic screening of women of childbearing age, with vaccination of seronegative nonpregnant women immediately and seronegative pregnant women after delivery. They also recommend universal vaccination of women of childbearing age without screening as an acceptable alternative. The Canadian Task Force does not recommend for or against universal vaccination of young men in settings where large numbers of young persons are gathered.⁹³

Discussion

When administered to children, the current rubella vaccine is efficacious in the induction of rubella immunity and in the prevention of rubella infection and CRS. Recent cases of rubella and CRS have been associated with outbreaks among groups of unvaccinated persons, leading to infections of unvaccinated pregnant women.^{4,7} The added coverage provided by the two MMR vaccinations many will receive during childhood to meet current recommendations for measles immunization (see Chapter 65) should eliminate most primary vaccine failures, and will increase the rate of primary immunization among women of childbearing age. Therefore, the incidence of CRS will probably decline as the current cohort of highly immunized female children and adolescents enters its childbearing years.

In the intervening years, however, many women of childbearing age will remain unimmunized and, therefore, susceptible to rubella infection. Universal screening and follow-up vaccination of susceptible females would reduce rubella susceptibility, infections, and CRS; however, the effectiveness of this strategy in the clinical setting may be limited by incomplete screening, imperfect screening tests, and failure to vaccinate susceptibles. Routine vaccination of all women of childbearing age, without screening, also seems to be effective in reducing rubella infections; it avoids the problem of noncompliance with return visits, and if given as MMR also provides immunity to other infectious diseases, but it results in vaccination of many women who are already immune. Because the adverse effects of vaccinating immune persons appear to be minimal, cost and convenience are likely to be the determining factors in deciding which strategy should be used. In one study, the most cost-effective strategy was record review followed by vaccination, if at least 75% of patients had records available; otherwise, vaccination of all persons without screening was most cost-effective.²³ On the other hand, a study from Iceland found that serologic screening of females

ages 12–40 followed by vaccination of seronegatives and follow-up retesting was more cost-effective than routine vaccination.⁹⁴ These estimates are sensitive to the prevalence of immunity, compliance with follow-up, and the costs of screening, vaccine, and follow-up.

Whether either strategy (screening for susceptibility or routine vaccination of women of childbearing age) is justified by expected benefits compared to costs is not clear. An analysis of a premarital rubella screening program found that costs did not justify benefits unless at least 85% of seronegatives were vaccinated.^{95,96} Variation in the cost of the screening tests and vaccines, the prevalence of immunity, and the likelihood of rubella exposure will influence these results, however. The impact and benefit-cost ratio of strategies to reduce rubella susceptibility are likely to be greatest in settings where many women are unvaccinated (and are therefore at higher risk for acquiring rubella), such as certain religious communities and communities with many unimmunized immigrants from developing countries. Cost-benefit analyses concerning rubella screening and vaccination of women in various settings are needed.

CLINICAL INTERVENTION

All children without contraindications should receive MMR vaccine at age 12–15 months and again at age 4–6 years (see Chapter 65). To reduce further the incidence of CRS, screening for rubella susceptibility by history of vaccination or by serology is recommended for all women of childbearing age at their first clinical encounter (“B” recommendation). A documented history of vaccination is more accurate than an undocumented history in determining rubella immunity and is therefore preferred. All susceptible nonpregnant women of childbearing age should be offered vaccination. Susceptible pregnant women should be vaccinated in the immediate post partum period. An equally acceptable alternative for nonpregnant women of childbearing age is to offer vaccination against rubella without screening (“B” recommendation). The decision of which strategy to use should be tailored to the individual clinician’s practice population, depending on the availability of vaccination records, the reliability of the vaccination history, the rate of immunity, the cost of serologic testing, and the cost and likelihood of follow-up vaccination for susceptible persons identified by serologic testing.

There is insufficient evidence to recommend for or against routine screening or vaccination of young men to prevent CRS in settings where large numbers of susceptible young adults of both sexes congregate, such as military bases and colleges (“C” recommendation). Recommendations to give MMR vaccine in these settings may be made on other grounds, however, such as prevention of measles (see Chapter 66). Routine screening or

vaccination of other young men, of older men, or of postmenopausal women, is not recommended (“D” recommendation).

Guidelines for the administration of MMR vaccine, and its contraindications, have been published by ACIP.¹ The National Childhood Vaccine Injury Act requires that the date of administration, the manufacturer and lot number, and the name, address, and title of the person administering the vaccine be recorded in the patient’s permanent medical record (or in a permanent office log or file).⁹⁷

The draft update of this chapter was prepared for the U.S. Preventive Services Task Force by Carolyn DiGiuseppi, MD, MPH.

REFERENCES

1. Centers for Disease Control. Rubella prevention: recommendations of the Advisory Committee for Immunization Practices (ACIP). *MMWR* 1990;39(RR-15):1–18.
2. Freij BJ, South MA, Sever JL. Maternal rubella and the congenital rubella syndrome. *Clin Perinatol* 1988;15:247–257.
3. Orenstein WA, Bart KJ, Hinman AR, et al. The opportunity and obligation to eliminate rubella from the United States. *JAMA* 1984;251:1988–1994.
4. Centers for Disease Control and Prevention. Rubella and congenital rubella syndrome—United States, January 1, 1991–May 7, 1994. *MMWR* 1994;43:391, 397–401.
5. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States—1991. *MMWR* 1992;40: 3–12.
6. Centers for Disease Control. Outbreaks of rubella among the Amish—United States, 1991. *MMWR* 1991;40: 264–265.
7. Centers for Disease Control. Increase in rubella and congenital rubella syndrome—United States, 1988–90. *MMWR* 1991;40:93–99.
8. Cradock-Watson JE. Laboratory diagnosis of rubella: past, present and future. *Epidemiol Infect* 1991;107:1–15.
9. Best JM. Rubella vaccines: past, present and future. *Epidemiol Infect* 1991;107:17–30.
10. Horstmann DM, Liebhaber H, Le Bouvier GL, et al. Rubella: reinfection of vaccinated and naturally immune persons exposed in an epidemic. *N Engl J Med* 1970;283:771–778.
11. Fayram SL, Akin S, Aarnæs SL, et al. Determination of immune status in patients with low antibody titers for rubella virus. *J Clin Microbiol* 1987;25:178–180.
12. Skendzel LP, Edson DC. Latex agglutination test for rubella antibodies: report based on data from the College of American Pathologists surveys, 1983–1985. *J Clin Microbiol* 1986;24:333–335.
13. Field PR, Ho DW, Cunningham AL. Evaluation of rubella immune status by three commercial enzyme-linked immunosorbent assays. *J Clin Microbiol* 1988;26:990–994.
14. Skendzel LP, Edson DC. Evaluation of enzyme immunosorbent rubella assays. *Arch Pathol Lab Med* 1985; 109:391–393.
15. Steece RS, Talley MS, Skeels MR, et al. Comparison of enzyme-linked immunosorbent assay, hemagglutination inhibition, and passive latex agglutination for determination of rubella immune status. *J Clin Microbiol* 1985; 21:140–142.
16. Kleeman KT, Kiefer DJ, Halbert SP. Rubella antibodies detected by several commercial immunoassays in hemagglutination inhibition-negative sera. *J Clin Microbiol* 1983;18:1131–1137.
17. Morgan-Capner P, Pullen HJM, Pattison JR, et al. A comparison of three tests for rubella antibody screening. *J Clin Pathol* 1979;32:542–545.
18. Robinson RG, Dudenhoefter FE, Holroyd HJ, et al. Rubella immunity in older children, teenagers, and young adults: a comparison of immunity in those previously immunized with those unimmunized. *J Pediatr* 1982;101:188–191.
19. Banatvala JE, Best JM, O’Shea S, Dudgeon JA. Persistence of rubella antibodies after vaccination: detection after experimental challenge. *Rev Infect Dis* 1985;7:S86–S90.

20. Balfour HH, Groth KE, Edelman CK. Rubella viraemia and antibody responses after rubella vaccination and reimmunisation. *Lancet* 1981;1:1078-1080.
21. Butler AB, Scott RM, Schydlower M, et al. The immunoglobulin response to reimmunization with rubella vaccine. *J Pediatr* 1981;99:531-534.
22. Buimovici-Klein E, O'Beirne AJ, Millian SJ, et al. Low level rubella immunity detected by ELISA and specific lymphocyte transformation. *Arch Virol* 1980;66:321-327.
23. Preblud SR, Gross F, Halsey NA, et al. Assessment of susceptibility to measles and rubella. *JAMA* 1982; 247:1134-1137.
24. Mills DA, Parker KR, Evans CE. Rubella antibody titres and immunization status in a family practice. *Can Med Assoc J* 1980;122:549-552.
25. Dales LG, Chin J. Public health implications of rubella antibody levels in California. *Am J Public Health* 1982;72: 167-172.
26. Nelson DB, Layde MM, Chatton TB. Rubella susceptibility in inner-city adolescents: the effect of a school immunization law. *Am J Public Health* 1982;72:710-713.
27. Cohen ZB, Rice LI, Felice ME. Rubella seronegativity in a low socioeconomic adolescent female population. *Clin Pediatr* 1985;24:387-390.
28. Orenstein WA, Herrmann KL, Holmgreen P, et al. Prevalence of rubella antibodies in Massachusetts schoolchildren. *Am J Epidemiol* 1986;124:290-298.
29. Schum TR, Nelson DB, Duma MA, et al. Increasing rubella seronegativity despite a compulsory school law. *Am J Public Health* 1990;80:66-69.
30. Murray DL, Lynch MA. Determination of immune status to measles, rubella, and varicella-zoster viruses among medical students: assessment of historical information. *Am J Public Health* 1988;78:836-838.
31. Chang TW, Desrosiers S, Weinstein L. Clinical and serologic studies of an outbreak of rubella in a vaccinated population. *N Engl J Med* 1970;283:246-248.
32. Grayston JT, Detels R, Chen KP, et al. Field trial of live attenuated rubella virus vaccine during an epidemic on Taiwan. *JAMA* 1969;207:1107-1110.
33. Davis WJ, Larson HE, Simsarian JP, et al. A study of rubella immunity and resistance to infection. *JAMA* 1971; 215:600-608.
34. Baba K, Yabuuchi H, Okuni H, et al. Rubella epidemic in an institution: protective value of live rubella vaccine and serological behavior of vaccinated, revaccinated, and naturally immune groups. *Biken J* 1978;21:25-31.
35. Greaves WL, Orenstein WA, Hinman AR, et al. Clinical efficacy of rubella vaccine. *Pediatr Infect Dis* 1983;2:284-286.
36. Horstmann DM, Schluederberg A, Emmons JE, et al. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection. *Rev Infect Dis* 1985;7(Suppl 1):S80-S85.
37. Hillary IB, Griffith AH. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. *Vaccine* 1988;2:274-276.
38. Enders G, Nickel U. Rubella vaccination: antibody persistence for 14-17 years and immune status of women without and with a history of vaccination. *Immun Infekt* 1988;16:58-64.
39. O'Shea S, Woodward S, Best JM, et al. Rubella vaccination: persistence of antibodies for 10-21 years [letter]. *Lancet* 1988;2:909.
40. Herrmann KL. Rubella in the United States: toward a strategy for disease control and elimination. *Epidemiol Infect* 1991;107:55-61.
41. Chen RT, Moses JM, Markowitz LE, et al. Adverse events following measles-mumps-rubella and measles vaccinations in college students. *Vaccine* 1991;9:297-299.
42. Wharton M, Cochi SL, Williams WW. Measles, mumps, and rubella vaccine. *Infect Dis Clin North Am* 1990;4:47-73.
43. Tingle AJ, Allen M, Petty RE, et al. Rubella-associated arthritis: I. Comparative study of joint manifestations associated with natural rubella infection and RA27/3 rubella immunization. *Ann Rheum Dis* 1986;45:110-114.
44. Lerman SJ, Nankervis GA, Heggie AD. Immunologic response, virus excretion, and joint reactions with rubella vaccine: a study of adolescent girls and young women given live attenuated virus vaccine (HPV-77:DE-5). *Ann Intern Med* 1971;74:67-73.
45. Landrigan PJ, Stoffels MA, Anderson E, et al. Epidemic rubella in adolescent boys: clinical features and results of vaccination. *JAMA* 1974;227:1283-1287.
46. Stehr-Green PA, Cochi SL, Preblud SR, et al. Evidence against increasing rubella seronegativity among adolescent girls [letter]. *Am J Public Health* 1990;80:88.

47. Lee SH, Ewert DP, Frederick PD, et al. Resurgence of congenital rubella syndrome in the 1990s. Report on missed opportunities and failed prevention policies among women of childbearing age. *JAMA* 1992; 267:2616–2620.
48. Povar GJ, Maloney M, Watson WN, et al. Rubella screening and follow-up immunization in Vermont. *Am J Public Health* 1979;69:285–286.
49. Falvo CE, Weiss KE, Liss SM. A rubella screening and immunization program in an adolescent clinic. *Am J Public Health* 1979;69:283–285.
50. Lieberman E, Faich GA, Simon PR, et al. Premarital rubella screening in Rhode Island. *JAMA* 1981; 245:1333–1335.
51. Vogt RL, Clark SW. Premarital rubella vaccination program. *Am J Public Health* 1985;75:1088–1089.
52. Miller CL, Miller E, Sequeira PJL, et al. Effect of selective vaccination on rubella susceptibility and infection in pregnancy. *BMJ* 1985;291:1398–1401.
53. Edmond E, Zealley H. The impact of a rubella prevention policy on the outcome of rubella in pregnancy. *Br J Obstet Gynaecol* 1986;93:563–567.
54. Trallero EP, Eguiluz GC, Iraeta MD, et al. Rubella in Guipuzcoa (Basque country, Spain). A four-year serosurvey. *Eur J Epidemiol* 1991;7:183–187.
55. Hartstein AI, Quan MA, Williams ML, et al. Rubella screening and immunization of health care personnel: critical appraisal of a voluntary program. *Am J Infect Control* 1983;11:1–9.
56. Weiss KE, Falvo CE, Buimovici-Klein E, et al. Evaluation of an employee health service as a setting for a rubella screening and immunization program. *Am J Public Health* 1979;69:281–283.
57. Polk BF, White JA, DeGirolami PC, et al. An outbreak of rubella among hospital personnel. *N Engl J Med* 1980;303:541–545.
58. Swartz TA, Hornstein L, Epstein I. Epidemiology of rubella and congenital rubella infection in Israel, a country with a selective immunization program. *Rev Infect Dis* 1985;7(suppl):S42–S46.
59. Galazka A. Rubella in Europe. *Epidemiol Infect* 1991;107:43–54.
60. Tobin JO, Sheppard S, Smithells RW, et al. Rubella in the United Kingdom, 1970–1983. *Rev Infect Dis* 1985;7(suppl):S47–S52.
61. Rafnar B. Rubella immunization of teenage girls in Iceland and follow-up after a severe rubella epidemic. *Bull WHO* 1982;60:141–146.
62. Zealley H, Edmond E. Rubella screening and immunisation of schoolgirls: results six to seven years after vaccination. *BMJ* 1982;284:382–384.
63. Gudmundsdottir S, Antonsdottir A, Guðnadottir S, et al. Prevention of congenital rubella in Iceland by antibody screening and immunization of seronegative females. *Bull WHO* 1985;63:83–92.
64. Griffiths PD, Baboonian C. Is post partum rubella vaccination worthwhile? *J Clin Pathol* 1982;35: 1340–1344.
65. Buser F, Nicolas A. Vaccination with RA27/3 rubella vaccine. *Am J Dis Child* 1971;122:53–56.
66. Schiff GM, Linnemann CC, Shea L, et al. Evaluation of RA27/3 rubella vaccine. *J Pediatr* 1974;85: 379–381.
67. Balfour HH, Balfour CL, Edelman CK, et al. Evaluation of Wistar RA27/3 rubella virus vaccine in children. *Am J Dis Child* 1976;130:1089–1091.
68. Weibel RE, Villarejos VM, Klein EB, et al. Clinical and laboratory studies of live attenuated RA27/3 and HPV-77DE rubella virus vaccines. *Proc Soc Exp Biol Med* 1980;165:44–49.
69. Plotkin SA, Farquhar JD, Katz M, et al. Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. *Am J Dis Child* 1969;118:178–185.
70. Plotkin SA, Farquhar JD, Ogra PL. Immunologic properties of RA27/3 rubella virus vaccine. *JAMA* 1973;225:585–590.
71. Bottiger M, Christenson B, Romanus V, et al. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. *BMJ (Clin Res Ed)* 1987;295:1264–1267.
72. Ukkonen P, von Bonsdorff C-H. Rubella immunity and morbidity: effects of vaccination in Finland. *Scand J Infect Dis* 1988;20:255–259.
73. Sheppard S, Smithells RW, Dickson A, et al. Rubella vaccination and pregnancy: preliminary report of a national survey. *BMJ* 1986;292:727.
74. Enders G. Rubella antibody titers in vaccinated and nonvaccinated women and results of vaccination during pregnancy. *Rev Infect Dis* 1985;7(Suppl 1):S103–S107.
75. Centers for Disease Control. Rubella vaccination during pregnancy—United States, 1971–1988. *MMWR* 1989;38: 289–293.

76. Losonsky GA, Fishaut JM, Strussenberg J, et al. Effect of immunization against rubella on lactation products. II. Maternal-neonatal interactions. *J Infect Dis* 1982;145:661–666.
77. Krogh V, Duffy LC, Wong D, et al. Postpartum immunization with rubella virus vaccine and antibody response in breast-feeding infants. *J Lab Clin Med* 1989;113:695–699.
78. Kaplan KM, Cochi SL, Edmonds LD, et al. A profile of mothers giving birth to infants with congenital rubella syndrome. *Am J Dis Child* 1990;144:118–123.
79. Centers for Disease Control. Rubella in universities—Washington, California. *MMWR* 1982;31:394–395.
80. Centers for Disease Control. Rubella in hospitals—California. *MMWR* 1983;32:37–39.
81. Centers for Disease Control. Rubella outbreak among office workers—New York City. *MMWR* 1985;34:455–459.
82. Heseltine PNR, Ripper M, Wohlford P. Nosocomial rubella—consequences of an outbreak and efficacy of a mandatory immunization program. *Infect Control* 1985;6:371–374.
83. Crawford GE, Gremillion DH. Epidemic measles and rubella in Air Force recruits: impact of immunization. *J Infect Dis* 1981;144:403–410.
84. Cote TR, Sivertson D, Horan JM, et al. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes. *Public Health Rep* 1993;108:431–435.
85. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States—1993. *MMWR* 1994;42 (53):1–73.
86. Bart KJ, Orenstein WA, Preblud SR, et al. Universal immunization to interrupt rubella. *Rev Infect Dis* 1985; 7(suppl):S177–S184.
87. American Academy of Pediatrics. Rubella. In: Peter G, ed. 1994 Red Book: report of the committee on infectious diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics, 1994:406–412.
88. American College of Obstetricians and Gynecologists. Rubella and pregnancy. *Technical Bulletin* no. 171. Washington, DC: American College of Obstetricians and Gynecologists, 1992:1–6.
89. American College of Physicians Task Force on Adult Immunization and Infectious Diseases Society of America. Guide for adult immunization. 3rd ed. Philadelphia: American College of Physicians, 1994:125–128.
90. American Medical Association. Guidelines for adolescent preventive services (GAPS). Chicago: American Medical Association, 1994:165–167.
91. Green M, ed. Bright Futures: guidelines for health supervision of infants, children, and adolescents. Arlington, VA: National Center for Education in Maternal and Child Health, 1994.
92. American Academy of Family Physicians. Age charts for periodic health examination. Kansas City, MO: American Academy of Family Physicians, 1994. (Reprint no. 510.)
93. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa: Canada Communication Group, 1994:126–135.
94. Gudnadottir M. Cost-effectiveness of different strategies for prevention of congenital rubella infection: a practical example from Iceland. *Rev Infect Dis* 1985;7:S200–S209.
95. Farber ME, Finkelstein SN. A cost-benefit analysis of a mandatory premarital rubella-antibody screening. *N Engl J Med* 1979;300:856–859.
96. McCormack WM, Gilfillan RF, Grady GF, et al. Cost-benefit analysis of rubella screening [letter]. *N Engl J Med* 1979; 301:216–217.
97. Centers for Disease Control. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination. *MMWR* 1988;37:197–200.